A.R.T. Advisors’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

A.R.T. Advisors’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-132	Closed	-$22K	–	314
2020 Q2	$22K	Buy	+132	New	+$22K	0.03%	252
2019 Q3	–	Sell	-148	Closed	-$90K	–	1865
2019 Q2	$90K	Buy	+148	New	+$90.8K	0.01%	1208
2019 Q1	–	Sell	-79	Closed	-$29K	–	1757
2018 Q4	$29K	Buy	+79	New	+$42.5K	﹤0.01%	1238
2018 Q2	–	Sell	-49	Closed	-$61K	–	1908
2018 Q1	$61K	Buy	+49	New	+$72.5K	﹤0.01%	1393

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KPWS

Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.35% 1-Year Est. Return

A.R.T. Advisors's NBRV Position: Q3 2020 in Review

A.R.T. Advisors sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2020, closing a stake of 132 shares — an estimated $22K sold.

A.R.T. Advisors first reported a position in NBRV in Q1 2018 and held it in 4 quarters. The position peaked at $90K in Q2 2019. 49 funds tracked by Wall St. Rank hold NBRV as of Q3 2020.

A.R.T. Advisors reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2020 after selling out during the quarter.
A.R.T. Advisors sold 132 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2020, an estimated $22K.
A.R.T. Advisors first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2018 and held it in 4 quarters.
A.R.T. Advisors's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $90K in Q2 2019.
49 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2020.

Based on A.R.T. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.